Tonghua Dongbao Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Tonghua Dongbao Pharmaceutical heeft een totaal eigen vermogen van CN¥6.4B en een totale schuld van CN¥492.7M, wat de schuld-eigenvermogensverhouding op 7.7% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥7.1B en CN¥693.9M. De EBIT Tonghua Dongbao Pharmaceutical is CN¥558.2M waardoor de rentedekking -4.8 is. Het heeft contanten en kortetermijnbeleggingen van CN¥372.8M.

Belangrijke informatie

7.7%

Verhouding schuld/eigen vermogen

CN¥492.75m

Schuld

Rente dekkingsratio	-4.8x
Contant	CN¥372.83m
Aandelen	CN¥6.43b
Totaal verplichtingen	CN¥693.87m
Totaal activa	CN¥7.12b

Recente financiële gezondheidsupdates

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Oct 22

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Jun 19

Recent updates

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Oct 22

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Sep 30

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Sep 06

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Sep 05

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Aug 22

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Jun 19

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

May 23

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥2.0B ) 600867 } overtreffen de korte termijn passiva ( CN¥455.8M ).

Langlopende schulden: De kortetermijnactiva 600867 ( CN¥2.0B ) overtreffen de langetermijnschulden ( CN¥238.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 1.9% ) 600867 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 600867 is de afgelopen 5 jaar gestegen van 2.5% naar 7.7%.

Schuldendekking: De schuld van 600867 wordt goed gedekt door de operationele kasstroom ( 124.5% ).

Rentedekking: 600867 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Tonghua Dongbao Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Recent updates

Consensus EPS estimates fall by 57%, revenue upgraded

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Investor sentiment improves as stock rises 16%

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Consensus revenue estimates fall by 32%

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Price target decreased by 9.8% to CN¥11.37

New minor risk - Earnings quality

New major risk - Dividend sustainability

Now 21% overvalued

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Consensus EPS estimates fall by 11%

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Price target decreased by 8.4% to CN¥13.15

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Price target increased by 7.4% to CN¥14.25

Price target increased by 8.2% to CN¥13.75

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Consensus EPS estimates fall by 10%, revenue upgraded

Second quarter 2023 earnings: EPS misses analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Price target increased by 14% to CN¥12.83

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥11.27

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 15%

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS exceeds analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Price target decreased to CN¥13.56

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

Price target decreased to CN¥14.96

New 90-day low: CN¥11.82

Full year 2020 earnings released: EPS CN¥0.46

Revenue behind estimates

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings miss expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans